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Angiotensin II regulates 11b-hydroxysteroid dehydrogenase
type 2 via AT2 receptors.
Background. In preeclampsia, cortisol degradation by the en-
zyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) is
compromised, which enhances intracellular cortisol availability.
This leads to vasoconstriction and renal sodium retention with
volume expansion, thus increasing blood pressure. An augmented
availability of angiotensin II (Ang II) predisposes to pre-
eclampsia. Some effects of Ang II are mediated by the mitogen-
activated protein kinase (MAPK) cascade, which also regulates
11-HSD2 activity. Therefore, we hypothesized that Ang II
regulates 11-HSD2.
Methods. The human choriocarcinoma cell line JEG-3, which
expresses the 11-HSD2 isoenzyme, was used. 3H-cortisol/cor-
tisone conversion assays and mRNA analyses by reverse tran-
scription-polymerase chain reaction (RT-PCR) were performed.
Cells were stimulated with Ang II and the effect was modulated
by Ang II type 1 (AT1) and AT2 receptor blockers DUP753
or L-158809 and PD-123319, respectively. In order to elucidate
the signaling cascade, the MAPK kinase inhibitors PD-098059
and U-0126 were probed. The impact of a modulated 11-
HSD2 activity was assessed by determining the effect of cortisol
on AT1 receptor mRNA.
Results. Ang II reduced mRNA and activity of 11-HSD2
mainly by a post-transcriptional mechanism. This Ang II effect
was abrogated by AT2, but not by AT1 receptor blockade.
Mitogen-activated protein (MAP) kinase kinase (MAPKK)
inhibitors reversed the Ang II effect. Dexamethasone aug-
mented the mRNA expression of AT1 receptors. Cortisol en-
hanced AT1 receptor mRNA expression when the 11-HSD2
activity was reduced either by Ang II or by glycyrrhetinic acid,
an 11-HSD2 inhibitor.
Conclusion. Ang II decreases the activity of 11-HSD2 by
an AT2 receptor– and MAPK-dependent mechanism. The de-
creased activity of 11-HSD2 increases the intracellular avail-
ability of cortisol, which might be relevant for the pathogenesis
of hypertension and preeclampsia.
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Preeclampsia is a widespread pregnancy-associated con-
dition characterized by arterial hypertension, protein-
uria, edema formation, and low fetal birthweight. De-
spite its enormous practical relevance, the underlying
mechanisms are not well defined. During pregnancy, blood
flow significantly increases in spiral arteries [1, 2]. Recent
studies underline the importance of fetal trophoblasts to
adapt maternal spiral arteries for this process [3]. In
preeclampsia, the uterine vascular resistance is increased,
resulting in a significant reduction of uteroplacental blood
flow [2, 4, 5].
Intracellular cortisol availability is regulated in the
kidney, the vasculature, and the placenta by the enzyme
11-hydroxysteroid dehydrogenase type 2 (11-HSD2),
which converts biologically active cortisol into inactive
cortisone [6]. The increased intracellular cortisol re-
sulting from a diminished 11-HSD2 activity enhances
renal sodium retention and vasoconstriction [7–9]. The
expression and activity of 11-HSD2 is reduced in pre-
eclampsia and intrauterine growth restriction, thus po-
tentially amplifying vasoconstriction of maternal vessels
[10, 11]. Intracellular pathways down-regulating the 11-
HSD2 include the mitogen-activated protein kinase
(MAPK) pathway, which is also a target for angiotensin
II (Ang II) [12, 13].
The blood pressure–regulating hormone Ang II plays
a crucial role in normal pregnancy and preeclampsia
[14–18]. Cellular signaling of Ang II is mediated via at
least two receptor subtypes with distinct modes of action,
the Ang II type 1 (AT1) and the AT2 receptor [reviewed
in 14]. The resistance to vascular effects of Ang II ob-
served in regular pregnancy is absent in women with hyper-
tensive pregnancies [19], an effect in line with an increased
number of vasoconstrictive AT1 receptors in women
with hypertensive pregnancies [20–23]. Glucocorticoids
enhance expression and activity of AT1A receptors and
decrease AT2 receptor expression [24], thus, the de-
creased activity of 11-HSD2 might contribute to an
altered pattern of AT receptors.
The interplay between Ang II/aldosterone and 11-
HSD2 is complicated and partially controversial. No ef-
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fect of physiologic concentrations of Ang II on 11-
HSD2 enzyme activity has been observed in the human
epithelial colon cell line SW-620 [25]. In rats, infusion
of Ang II did not affect tubular 11-HSD2 mRNA, deter-
mined by semiquantitative reverse transcription-poly-
merase chain reaction (RT-PCR); similarly, the activity
of 11-HSD2 was unaffected in isolated tubules follow-
ing short-term incubation with Ang II [26]. In contrast,
in vitro addition of Ang II to rat medullary renal tissue
reduced 11-HSD2 activity [27].
The present study was performed to elucidate whether
Ang II can regulate 11-HSD2 activity. To explore this
hypothesis, we exploited the human choriocarcinoma cell
line JEG-3. This cell line displays an endothelial pheno-
type and exhibits oxidative 11-HSD2 activity only [28, 29].
METHODS
Materials
Cell culture material was from Becton Dickinson
Labware (Basel, Switzerland), and Corning (Boden-
heim, Germany). Cortisol, dexamethasone, glycyrrheti-
nic acid, Eagle’s minimal essential medium (MEME),
and transferrin were purchased from Sigma Chemical
(Buchs, Switzerland). PD-098059, DUP-753, PD-123319,
Ang II, Ang III, and actinomycin D were obtained from
Calbiochem-Novabiochem (La Jolla, CA, USA). 3H-cor-
tisol (specific activity 2.33 TBq/mmol) was purchased
from Amersham (Buckinghamshire, UK). L-158809 was
a generous gift by Merck Sharp & Dohme-Chibret (Glatt-
brugg, Switzerland). TLC plates (silica gel 60F254) were
obtained from Macherey-Nagel (Oensingen, Switzerland),
U-0126 from Promega ( Wallisellen, Switzerland), fetal calf
serum (FCS) from Biological Industries (Mame-la-Vallee,
France), and primers from Microsynth (Balgach, Switzer-
land). The human choriocarcinoma cell line JEG-3, which
we extensively characterized earlier [28], was obtained
from American Type Cell Culture (HTB-36; ATCC,
Manassas, VA, USA).
Cell culture
The human choriocarcinoma cell line JEG-3 was used
for subsequent experiments, cultured in MEME supple-
mented with 10% FCS, 2 mmol/L glutamate, 100 U/mL
penicillin, and 100 g/mL streptomycin, passaged with
trypsin/ethylenediaminetetraacetic acid (EDTA), plated
in cell culture dishes, grown to confluence, and washed
twice with phosphate-buffered saline (PBS), pH 7.4, at
37C before starting the experiments. The porcine renal
tubular epithelial cell line LLC-PK, cultured as described
elsewhere [12], was used additionally. At the completion
of each experiment, cells were again washed twice with
ice-cold PBS and the experiment proceeded according
to subsequent protocols. Incubations were performed
for 24 hour periods, if not otherwise indicated.
Assay for 11-HSD activity in cell homogenates
Human JEG-3 and porcine LLC-PK cells were scraped
and lysed in sucrose buffer (250 mmol/L sucrose, 2
mmol/L EDTA, 20 mmol/L Tris-HCl, pH 7.5), and the
supernatant stored at 20C. Protein content was deter-
mined using the Bradford protein assay (Bio-Rad, Glatt-
brugg, Switzerland). The cortisol/cortisone conversion
was used to measure oxidation at C-11 by 11-HSD2 in
the presence and absence of Ang II and Ang III following
protocols described earlier [28]. In brief, cell homoge-
nates were incubated with 5 nCi [3H]-cortisol, 10 nmol/L
corticosterone, and 200 mol/L nicotinamide adenine
dinucleotide in sucrose buffer. The reaction was stopped
by adding 20 L of 1 mg/mL unlabeled cortisol and corti-
sone in methanol and thin layer chromatography (TLC)
developed in chloroform-methanol (90:10 vol/vol). Ste-
roids were located using ultraviolet light, excised, and
counted in a Packard scintillation counter (Tri Carb
2000CA; United Technologies, Hartford, CT, USA).
Specific activity was expressed as pmol per mg protein
per hour. The assay was repeated up to 4 times using
different protein concentrations within each individual
experiment.
Reverse transcription and PCR
Transcripts of 11b-HSD2 by TaqMan PCR. The se-
quences of primers and probes for 11-HSD2 and glycer-
aldehydes-3-phoshate dehydrogenase (GAPDH), which
served as an internal standard, were the same as pub-
lished earlier [28]. Reverse transcription (RT) of 5 g
of total RNA in the presence of oligo-(dT)12-18 primer
and 200 U Moloney-murine leukemia virus (MMLV)-
reverse transcriptase (both by Gibco-BRL, Gaithers-
burg, MD, USA) was followed by polymerase chain reac-
tion (PCR) performed in a Perkin Elmer ABI Prism
7700 Thermal Cycler Sequence Detection System (Per-
kin Elmer/Applied Biosystems, Foster City, CA, USA)
using ABI Prism PrimerExpress Software (Applied Bio-
systems). 11-HSD2 PCR product was normalized by
the GAPDH PCR product.
Transcripts of AT1 and AT2 receptors. Five g of total
RNA of JEG-3 cells were subjected to a RT-reaction
using oligo-(dT)12-18 and 200 U MMLV reverse tran-
scriptase according to the protocol as proposed by the
supplier (Invitrogen, Carlsbad, CA, USA). Specific prim-
ers for the homology-based PCR (performed at 35 and
40 cycles of 1 minute of denaturation at 95C, 1 minute
of annealing at 60C, and 1 minute, 30 seconds of exten-
sion at 72C) produced PCR products of the expected
sizes of the AT1 and AT2 receptors, respectively. Nega-
tive controls as provided by sham RNA extraction for
the RT and the PCR reagents remained negative. Con-
tamination of RNA by genomic DNA was excluded by
directly subjecting the RNA to PCR amplification with-
out RT step.
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Primer sequences for the human AT1 receptor were:
sense, 5-GATGATTGTCCCAAAGCT-3, antisense,
5-TAGGTAATTGCCAAAGGGCC-3 (position 261
to 278 and 515 to 496, respectively, of NM_032049.1), and
for the human AT2 receptor: sense, 5-AGGAATTC
ACTCCACCCTTGCCACTA-3, antisense, 5-ACGG
ATCCGTCACGGGTTATCCTGTT-3 (position 173 to
190 and 918 to 901, respectively, of NM_000686.3) (added
restriction sites are underlined).
Quantitative RT-PCR analysis of AT1 receptor expressi-
on. Dilution series of cDNA pools of cultured JEG-3
cells, prepared as described above, were used to amplify
the AT1 receptor cDNA and GAPDH: sense, 5-AG
GAATTCGGAGTCCACTGGCGTCTTC-3 and anti-
sense, 5-ACGGATCCTGTCATCATATTTGGCAG
GTT-3 (position 363 to 381 and 846 to 827, respectively,
of XM_006959.1). Ethidium bromide–stained agarose
gels were densitometrically assessed and the AT1/GAPDH
ratio was calculated. Results were expressed as arbitrary
densitometrical units.
Western blot analysis of AT1 and AT2 receptors
Preparation of JEG-3 cell lysates and immunoblot
analysis was performed in control conditions as de-
scribed earlier [30]. Briefly, the medium was removed,
and the plates were washed twice with ice-cold PBS.
Thereafter, cells were scraped into 450 L of sucrose
buffer (250 mmol/L sucrose, 2 mmol/L EDTA, 20 mmol/L
Tris-HCl, pH 7.5). The cell lysates were collected in
centrifuge tubes after boiling and spinning at 12,000g for
5 minutes at 4C. Protein contents were determined. The
samples (50 g) were diluted in electrophoresis sample
buffer (250 mmol/L Tris, pH 6.8, 4% SDS, 10% glycerol,
0.006% bromophenol blue, 2% mercaptoethanol) boiled
for 5 minutes, quenched on ice, and resolved by electro-
phoresis through 0.1% SDS-10% polyacrylamide gels.
Proteins were electrophoretically transferred to nitrocel-
lulose membranes (Amersham, Braunschweig, Germany).
The transfer efficiency was determined by staining the
membranes with Ponceau S solution. After destaining
in distilled water, the membranes were quenched in
blocking solution [5% powdered dried low-fat milk in
washing solution (10 mmol/L Tris, pH 7.5, 100 mmol/L
NaCl, 0.1% Tween 20)] overnight at 4C. The blocking
solution was decanted, membranes incubated for 2 hours
at room temperature (RT) with the primary antibodies
(rabbit anti-AT1 and goat anti-AT2, respectively, poly-
clonal, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Membranes were washed for 30 minutes at RT with
several changes of the washing solution. The secondary
detecting antibody was horseradish peroxidase–conjugated
anti-rabbit and anti-goat immunoglobulin G (IgG), re-
spectively (1:5000; Santa Cruz Biotechnology), which
were used with the enhanced chemiluminescence (ECL)
protocol (Amersham).
Fig. 1. Angiotensin II (Ang II)–induced reduction of 11-hydroxyste-
roid dehydrogenase type 2 (11-HSD2) activity in JEG-3 cells. Mean 
SEM (N  4 to 6) are given. *P  0.01, and **P  0.02 vs. untreated
control.
Statistical analysis
Mean  standard error of the mean were determined.
To test for statistically significant differences (P  0.05),
Student t test, analysis of variance (ANOVA), or multi-
ple comparisons versus control group (Tukey test) were
used, as appropriate.
RESULTS
The 11-HSD2 activity of cultured JEG-3 cells in
response to Ang II
In JEG-3 cell homogenates, 11-HSD2 enzyme activ-
ity was present as shown by the 3H-cortisol to 3H-corti-
sone conversion [28, 29]. Adding Triton X-100 to the
11-HSD assay mixture abolished the enzyme activity,
an observation indicating that the activity is attributable
to 11-HSD2 and not to 11-HSD1 enzyme, a contention
supported by the expression of 11-HSD2, but not 11-
HSD1, mRNA [28]. This conversion was almost com-
pletely inhibited in the presence of glycyrrhetinic acid
(106 mol/L) (data not shown). Addition of Ang II (109
to 106 mol/L) for 24 hours to the cell cultures dose
dependently reduced the 11-HSD2 activity in JEG-3
cells with Ang II at 107 mol/L, providing the lowest
11-HSD2 activity (Fig. 1). Further increase in Ang II
concentrations showed no further inhibition of 11-
HSD2 activity (51  16% of baseline at Ang II 106
mol/L). No effect of Ang II (107 to 106 mol/L) on 11-
HSD2 activity of LLC-PK cells was observed (data not
shown). Time course experiments up to 24 hours indi-
cated a reduction in 11-HSD2 activity as early as 4
hours following the addition of Ang II (107 mol/L). The
effect of Ang II was gradually reversible within 24 hours
after removing Ang II (Fig. 2).
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Fig. 2. Angiotensin II (Ang II) reduced time dependently and revers-
ibly 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) activity in
JEG-3 cells. Mean  SEM (N  4 to 8 for each time point) are given.
*P  0.05 vs. time control without Ang II.
Fig. 3. Angiotensin II (Ang II) (107 mol/L) extended the terminal
half-life (T1⁄2) of 11-hydroxysteroid dehydrogenase type 2 (11-HSD2)
mRNA in JEG-3 cells. Actinomycin D (Act D, 10 g/mL) was used to
inhibit production of new transcripts at 0 hours. Mean  SEM (N 
5 to 9) are given. *P  0.05 vs. time control.
Stability of 11-HSD2 mRNA in JEG-3 cells in
response to Ang II
Using TaqMan (Applied Biosystems) RT-PCR, re-
duced steady state levels of 11-HSD2 mRNA were de-
tected after 24 hours of incubation with Ang II (40 
10% of control, N  6). When transcription was blocked
with actinomycin D (10 g/mL), a half-life of 28.1 hours
was observed (Fig. 3). This half-life was shortened by
46% (Fig. 3) if cells were incubated simultaneously with
actinomycin D (10 g/mL) and Ang II (107 mol/L).
Actinomycin D toxicity precluded to extend these exper-
iments beyond 16 hours. The translational inhibitor
Fig. 4. Angiotensin II (Ang II) reduced 11-hydroxysteroid dehydro-
genase type 2 (11-HSD2) activity via angiotensin II receptor type 2
(AT2) but not via angiotensin II type 1 (AT1) receptors in JEG-3 cells.
Receptor-specific blockade was by DUP-753 (DUP) for the AT1 and
by PD-123319 (PD) for the AT2 receptor. Mean  SEM (N  5 to 8)
are given. *P  0.05 vs. no Ang II.
cycloheximide (5 g/mL) stabilized 11-HSD2 mRNA
in control experiments (188  28%; P  0.05 vs. un-
treated control), as well as following coincubation with
Ang II (107 mol/L) (174  10%; P  0.05 vs. untreated
control).
Inhibition of 11-HSD2 activity is specific to AT2
receptors via the MAP kinase kinase as regulatory
downstream signaling event
Incubation of JEG-3 cells for 24 hours with the AT1
and AT2 specific inhibitors DUP-753 or PD-123319
(both at 106 mol/L) [30] in the absence of Ang II did
not influence cortisol/cortisone conversion (Fig. 4). The
inhibition of cortisol/cortisone conversion by Ang II
(107 mol/L) was not abolished by the AT1 receptor
antagonist DUP-753 (Fig. 4) or L-158809 (2.5 	 106
mol/L, results not shown), but by the AT2 receptor an-
tagonist PD-123319 (Fig. 4).
AT2 receptor signals include the MP1-scaffolded mito-
gen-activated protein (MAP) kinase (MAPK) cascade.
To elucidate its role in Ang II–dependent 11-HSD2
inhibition, cells were incubated with the MAPK kinase
inhibitors PD-098059 (2.5	 105 mol/L) and U-0126 (105
mol/L), respectively. In the absence of Ang II, neither
PD-098059 nor U-0126 modulated 11-HSD2 activity.
Ang II (107 mol/L) reduced 11-HSD2 activity by 59 
5%, which was partially restored by the MAPK inhibitor
U-0126 to 71  2% of baseline activity and completely
restored by PD-098059 (95  7% of baseline activity)
(Fig. 5).
Availability of AT1 and AT2 receptors
RT-PCR was performed with RNA of JEG-3 cells.
Restriction analysis and sequencing of PCR products
indicated the presence of AT1, as well as of AT2 recep-
tors (Fig. 6). Negative controls for the RT and PCR were
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Fig. 5. Angiotensin II (Ang II) inhibited 11-hydroxysteroid dehydro-
genase type 2 (11-HSD2) via AT2-dependent mitogen-activated pro-
tein kinase (MAPK) signaling. Ang II inhibition of 11-HSD2 activity
was completely reversed by the mitogen-activated protein kinase kinase
(MEK)1/2 inhibitor PD-098059 (PD59) and partially by U-0126 (U).
Mean  SEM (N  4 to 7) are given. *P  0.001 vs. no Ang II, §P 
0.001 vs. Ang II.
negative. The presence of protein of both AT receptors
was verified by Western blot analysis in JEG-3 cellular
extracts.
AT1 receptor mRNA was not affected if glycyrrhetinic
acid (106 mol/L) or Ang II (107 mmol/L) were added
in the absence of cortisol (3  16% and 7  14%
change to control, respectively). Addition of cortisol
(106 mmol/L) to JEG-3 cells with intact 11-HSD2 ac-
tivity left the AT1 receptor expression equally un-
changed (2  14% change to control). Inhibition of
11-HSD2 activity, either by 24 hour incubation with
Ang II (107 mol/L) or with glycyrrhetinic acid (106
mol/L) in the presence of cortisol (106 mol/L) increased
the AT1 receptor mRNA expression (Fig. 7). A compa-
rable enhanced expression of AT1 receptors was ob-
served when dexamethasone (106 mol/L), a glucocorti-
coid not inactivated by 11-HSD2, was added to the cell
culture.
DISCUSSION
The pathophysiology of preeclampsia is a much de-
bated, unresolved issue. During normal pregnancies, the
renin-Ang II-aldosterone system is activated, yet the
high Ang II plasma concentrations are not transduced
into elevated blood pressure. In preeclampsia, this resis-
tance to Ang II in normal pregnancy is converted into
an abnormal Ang II sensitivity [19].
Besides a critical role of Ang II availability [16, 17],
evidence is growing for an altered balance of AT1 and
AT2 receptors in preeclampsia. Vasoconstrictive AT1
receptors are multiplied and/or activated [20–22]. Acti-
vation of AT1 receptors results in vasoconstriction,
which might limit fetal blood and substrate supply [21].
Glucocorticoids stimulate transcription of AT1 receptors
[32]. The availability of cortisol to the intracellular recep-
tor is regulated by 11-HSD enzymes. The pronounced
expression of 11-HSD2 in the uteroplacental circulation
supports the potential regulatory role of this enzyme for
mechanisms involved in arterial hypertension, volume
expansion, and/or vasoconstriction. Furthermore, exper-
iments in pregnant ewes suggested a role for AT2 recep-
tors to maintain an adequate uteroplacental blood sup-
ply; these receptors are down-regulated by an enhanced
exposure to Ang II [31].
During preeclampsia blood supply to the placenta is
compromised. The vascular trophoblast represents the
crucial regulatory element controlling placental blood
supply in vivo. Thus, JEG-3 cells were used as a model
to investigate the effects of Ang II on 11-HSD2. In
these cells, Ang II inhibited the activity of 11-HSD2
dose dependently and reversibly. In contrast, we did not
observe an inhibitory effect of Ang II on 11-HSD2 in
cultured renal tubular LLC-PK1 cells, which express
AT1, but virtually no AT2 receptors [33]. Riddle et al
[27] showed that Ang II inhibits 11-HSD activity in
renal tissue slices. In two other studies, such an inhibitory
effect of Ang II on 11-HSD activity was only observed
when supraphysiologic, but not when lower, concentra-
tions of Ang II were considered [25, 26]. The reasons
for these differences are unknown. It is conceivable that
they are due to differences in experimental procedures,
cellular matrices used, and/or AT receptor expression.
The cells investigated in studies without an effect of Ang
II were either ex vivo tubule preparations from rats or
epithelial colon cells, whereas in the present investiga-
tion 11-HSD2 inhibition was present in a human cell
line with an endothelial phenotype. No experimental
evidence for the presence of AT receptors in the cell
lines and kidney tubules without response to Ang II was
given [25, 26]. Given the specific AT2-mediated Ang II
effect on the 11-HSD2 enzyme observed in our study,
this information would have been important for the
proof of absence of an effect of Ang II.
Ang II–dependent reduction of 11-HSD2 activity in
the present investigation is best explained by a decreased
abundance of 11-HSD2 mRNA. The control of tran-
script availability has previously been demonstrated as
a regulatory step of 11-HSD2 activity [28, 29, 34]. Ang
II led to a reduction of the terminal half-life of 11-HSD2
mRNA as an underlying mechanism for diminished 11-
HSD2 mRNA levels. Ang II–induced destabilization of
11-HSD2 mRNA is prevented by the translational in-
hibitor cycloheximide, suggesting that the induction of
an unknown factor is required to mediate this effect.
A candidate-binding region could not be derived from
existing databases. Ang II–induced destabilization of
mRNA is in line with previous observations by Nickenig
and Murphy [35] in aortic smooth muscle cells where
polyribosomal proteins binding to the distal 350 bases
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Fig. 6. Angiotensin II receptor type 1 (AT1)
and angiotensin II receptor type 2 (AT2) re-
ceptor mRNA and protein is expressed in
JEG-3 cells. The AT1 and the AT2 receptor
polymerase chain reaction (PCR) products
were sequenced and analyzed by restriction
digests with RcaI and HaeIII, respectively.
The resulting fragments were size-separated
on an ethidium-bromide agarose gel. Presence
of AT1 and AT2 receptor protein is presented
by Western blot analysis. Representative ex-
periments are shown.
Fig. 7. Angiotensin II (Ang II), glycyrrhetinic acid (GA), and dexa-
methasone (Dexa) significantly increased the angiotensin II receptor
type 1 (AT1) receptor mRNA expression in cultured JEG-3 cells. The
level of mRNA of AT1 receptor and glyceraldehydes phosphate dehy-
drogenase (GAPDH) was determined and the ratios were calculated.
These ratios are expressed as mean  SEM (N  4 to 6) percentage
increase compared to control. *P  0.04 and **P  0.03 vs. untreated
control.
of the AT1 receptor mRNA were induced. Other aspects
of Ang II modulation influencing the activity of 11-
HSD2, such as post-translational modifications or its in-
tracellular localization, have not been a focus of the
present study.
Inhibition of 11-HSD2 activity by Ang II is AT2
receptor–dependent, a conclusion supported first by add-
ing Ang II to JEG-3 cellular extracts in vitro to exclude
receptor-independent direct inhibition of the 11-HSD2
enzyme by Ang II, second, by abrogating the Ang II
effect with an AT2, but not an AT1 receptor blocker,
and third, by demonstrating inhibition of 11-HSD2 by
Ang II in the AT2 receptor expressing JEG-3, but not
in the LLC-PK1 cells, which exhibit virtually no AT2
receptors. The intracellular signaling cascade down-
stream of the AT2 receptor comprises the MAPK cas-
cade [36]. In JEG-3 cells, Ang II–mediated regulation
of 11-HSD2 depends upon this pathway, an observation
in line with previous studies from our group demonstra-
ting a similar MAPK-dependent down-regulation of the
11-HSD2 enzyme by tumor necrosis factor-
 (TNF-
)
or hypoxemia [12, 37]. According to our observations,
Ang II signaling via the MAPK cascade might be attrib-
uted to Sp1 sites, which regulate the 11-HSD2 promotor
[38]. Angiotensin III (Ang III), which was reported to
activate AT2 receptors [39], had no effect on the expres-
sion of 11-HSD2 in JEG-3 cells (data not shown). As
for Ang II, a receptor-independent effect was excluded
by incubating cellular extracts containing 11-HSD2 en-
zyme with Ang III in vitro.
Dexamethasone is known to enhance the expression
of AT1A receptors in several tissues [32]. Inhibition of
11-HSD2 by Ang II or glycyrrhetinic acid reduces the
conversion of biologically active cortisol into inactive
cortisone and therefore, as expected, activates glucocor-
ticoid-dependent expression of AT1 receptor mRNA
(Fig. 7). Dexamethasone, which activates glucocorticoid
responsive elements of the rat AT1A receptor promoter,
served as control [24]. Evidence for a functional rele-
vance of glucocorticoid-mediated up-regulation of AT1
receptors has previously been demonstrated by our
group in a model of cultured rat mesangial cells [30].
As shown in the present investigation, Ang II mediates
increased intracellular availability of cortisol, which might
promote vasoconstriction by increasing AT1 receptors
and decrease uteroplacental perfusion. A glucocorticoid-
induced vasoconstriction due to a reduced 11-HSD2
Lanz et al: Angiotensin II and 11b-HSD2976
has been described in other models, such as in isolated
aortic rings from rats [7, 40]. In neonatal sheep, maternal
malnutrition during gestation was accompanied by a de-
creased 11-HSD2 mRNA and an increased AT1 recep-
tor expression [41]. In women with preeclampsia, up-
regulation of AT1 receptors including increased AT1
receptor heterodimers and a decreased activity of 11-
HSD2 have been reported [10, 11, 22, 23], observations
suggesting a link between 11-HSD2 and AT1 receptors.
CONCLUSION
Ang II decreases the activity of 11-HSD2 by an AT2
receptor– and MAPK-dependent mechanism. The de-
creased activity of 11-HSD2 increases the intracellular
availability of cortisol, which might be relevant for the
pathogenesis of hypertension and preeclampsia.
ACKNOWLEDGMENTS
This work has been supported by a grant for scientific research from
the Swiss National Science Foundation (No. 3200-055869.98/1).
Reprint requests to Markus G. Mohaupt, M.D., University Hospital
Berne, Division of Nephrology/Hypertension 3010 Berne, Switzerland.
E-mail: markus.mohaupt@insel.ch
REFERENCES
1. Assali NS, Douglas RA, Baird WW: Measurement of uterine
blood flow and uterine metabolism. Am J Obstet Gynecol 66:248–
256, 1953
2. Beinder E, Mohaupt M, Schlembach D, et al: Nitric oxide synthase
activity and doppler parameters in the fetoplacental and uteropla-
cental circulation in preeclampsia. Hypertens Pregnancy 18:115–
129, 1999
3. Zhou Y, Fisher SJ, Janatpour M, et al: Human cytotrophoblasts
adopt a vascular phenotype as they differentiate. A strategy for
successful endovascular invasion? J Clin Invest 99:2139–2151, 1997
4. Weis EB, Bruns PD, Taylor ES: A comparative study of the
disappearance of radioactive sodium from human uterine muscle in
normal and abnormal pregnancy. Am J Obstet Gynecol 76:340–346,
1958
5. Roberts JM, Cooper DW: Pathogenesis and genetics of pre-
eclampsia. Lancet 357:53–56, 2001
6. Pepe GJ, Burch MG, Albrecht ED: Localization and develop-
mental regulation of 11-hydroxysteroid dehydrogenase-1 and -2
in the baboon syncytiotrophoblast. Endocrinology 142:68–80, 2001
7. Brem AS, Bina RB, Hill N, et al: Effects of licorice derivatives
on vascular smooth muscle function. Life Sci 60:207–214, 1997
8. Hadoke PWF, Christy C, Kotelevtsev YV, et al: Endothelial cell
dysfunction in mice after transgenic knockout of type 2, but not
type 1, 11-hydroxysteroid dehydrogenase. Circulation 104:2832–
2837, 2001
9. Hatakeyama H, Inaba S, Miyamori I: 11-hydroxysteroid dehy-
drogenase in cultured human vascular cells. Hypertens 33:1179–
1184, 1999
10. McCalla CO, Nacharaju VL, Muneyyirci-Delale O, et al: Pla-
cental 11-hydroxysteroid dehydrogenase activity in normotensive
and pre-eclamptic pregnancies. Steroids 63:511–515, 1998
11. Shams M, Kilby MD, Somerset DA, et al: 11-hydroxysteroid
dehydrogenase type 2 in human pregnancy and reduced expression
in intrauterine growth restriction. Hum Reprod 13:799–804, 1998
12. Heiniger CD, Rochat MK, Frey FJ, Frey BM: TNF-
 enhances
intracellular glucocorticoid availability. FEBS Lett 507:351–356,
2001
13. Inagami T, Eguchi S, Numaguchi K, et al: Cross-talk between
angiotensin II receptors and the tyrosine kinases and phosphatases.
J Am Soc Nephrol 10:S57–S61, 1999
14. De Gasparo M, Catt KJ, Inagami T, et al: International Union
of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol
Rev 52:415–472, 2000
15. Morgan T, Craven C, Ward K: Human spiral artery renin-angio-
tensin system. Hypertens 32:683–687, 1998
16. Li C, Ansari R, Yu Z, Shah D: Definitive molecular evidence of
renin-angiotensin system in human uterine decidual cells. Hyper-
tens 36:159–164, 2000
17. Arngrimsson R, Purandare S, Connor M, et al: Angiotensinogen:
A candidate gene involved in preeclampsia. Nat Genet 4:114–115,
1993
18. August P, Lenz T, Ales KL, et al: Longitudinal study of the renin-
angiotensin-aldosterone system in hypertensive pregnant women:
Deviations related to the development of superimposed pre-
eclampsia. Am J Obstet Gynecol 163:1612–1621, 1990
19. Gant NF, Daley GL, Chand S, et al: A study of angiotensin II
pressor response throughout primigravid pregnancy. J Clin Invest
52:2682–2689, 1973
20. Baker PN, Broughton Pipkin F, Symonds EM: Comparative study
of platelet angiotensin II and angiotensin II sensitivity tests as
predictors of pregnancy-induced hypertension. Clin Sci Colch
83:89–95, 1992
21. Doering TP, Haller NA, Montgomery MA, et al: The role of
AT1 angiotensin receptor activation in the pathogenesis of pre-
eclampsia. Am J Obstet Gynecol 178:1307–1312, 1998
22. Leung PS, Tsai SJ, Wallukat G, et al: The upregulation of angio-
tensin II receptor (AT1) in human preeclamptic placenta. Mol Cell
Endocrinol 184:95–102, 2001
23. Abdalla S, Lother H, El Massiery A, Quitterer U: Increased
AT1 receptor heterodimers in preeclampsia mediate enhanced an-
giotensin II responsiveness. Nat Med 7:1003–1009, 2001
24. Guo DF, Uno S, Ishihata A, et al: Identification of a cis-acting
glucocorticoid responsive element in the rat angiotensin II type
1A promotor. Circ Res 77:249–257, 1995
25. Ricketts ML, Stewart PM: Regulation of 11-hydroxysteroid de-
hydrogenase type 2 by diuretics and the renin-angiotensin-aldoste-
rone axis. Clin Sci 96:669–675, 1999
26. Hermans J Jr, Fischer MA, Schiffers PM, Struijker-Boudier
HA: Effect of angiotensin II on rat renal cortical 11-hydroxyste-
roid dehydrogenase. Endocrine 13:393–399, 2000
27. Riddle MC, McDaniel PA: Renal 11-hydroxysteroid dehydroge-
nase activity is enhanced by ramipril and captopril. J Clin Endocri-
nol Metab 78:830–834, 1994
28. Lanz C-B, Causevic M, Heiniger CD, et al: Fluid shear stress
reduces 11-hydroxysteroid dehydrogenase type 2. Hypertens
37:160–169, 2001
29. Pasquarette MM, Stewart PM, Ricketts ML, et al: Regulation
of 11-hydroxysteroid dehydrogenase type 2 activity and mRNA
in human choriocarcinoma cells. J Mol Endocrinol 16:269–275,
1996
30. Schwo¨bel J, Fischer T, Lanz B, Mohaupt MG: Angiotensin II
receptor subtypes determine induced nitric oxide production in
rat glomerular mesangial cells. Am J Physiol 279:F1092–F1100,
2000
31. McMullen JR, Gibson KJ, Lumbers ER, Burrell JH: Selective
down-regulation of AT(2) receptors in uterine arteries from preg-
nant ewes given 24-h intravenous infusions of angiotensin II. Regul
Pept 99:119–129, 2001
32. Chansel D, Llorens-Cortes C, Vandermeersch S, et al: Regula-
tion of angiotensin II receptor subtypes by dexamethasone in rat
mesangial cells. Hypertens 27:867–874, 1996
33. Wolf G, Zahner G, Mondorf U, et al: Angiotensin II stimulates
cellular hypertrophy of LLC-PK1 cells through the AT1 receptor.
Nephrol Dial Transplant 8:128–133, 1993
34. Sun K, Yang K, Challis JR: Regulation of 11-hydroxysteroid
dehydrogenase type 2 by progesterone, estrogen, and the cyclic
adenosine 5-monophosphate pathway in cultured human placental
and chorionic trophoblasts. Biol Reprod 58:1379–1384, 1998
Lanz et al: Angiotensin II and 11b-HSD2 977
35. Nickenig G, Murphy TJ: Enhanced angiotensin receptor type 1
mRNA degradation and induction of polyribosomal mRNA bind-
ing proteins by angiotensin II in vascular smooth muscle cells. Mol
Pharmacol 50:743–751, 1996
36. Gendron L, Laflamme L, Rivard N, et al: Signals from the AT2
(angiotensin type 2) receptor of angiotensin II inhibit p21ras and
activate MAPK (mitogen-activated protein kinase) to induce mor-
phological neuronal differentiation in NG108–15 cells. Mol Endo-
crinol 13:1615–1626, 1999
37. Heiniger CD, Kostadinova RM, Rochat MK, et al: Hypoxia
causes down-regulation of 11-hydroxysteroid dehydrogenase type
2 by induction of Egr-1. FASEB J 17:917–919, 2003.
38. Nawrocki AR, Goldring CE, Kostadinova RM, et al: In vivo
footprinting of the human 11-hydroxysteroid dehydrogenase type
2 promotor: Evidence for cell-specific regulation by Sp1 and Sp3.
J Biol Chem 277:14647–14656, 2002
39. Lorenzo O, Ruiz-Ortega M, Suzuki Y, et al: Angiotensin III
activates nuclear transcription factor-B in cultued mesangial cells
mainly via AT2 receptors: studies with AT1 receptor-knockout
mice. J Am Soc Nephrol 13:1162–1171, 2002
40. Ullian ME, Hazen-Martin DJ, Walsh LG, et al: Carbenoxolone
damages endothelium and enhances vasoconstrictor action in aor-
tic rings. Hypertens 27:1346–1352, 1996
41. Whorwood CB, Firth KM, Budge H, Symonds ME: Maternal
undernutrition during early to midgestation programs tissue-specific
alternations in the expression of the glucocorticoid receptor, 11-
hydroxysteroid dehydrogenase isoforms, and type 1 angiotensin II
receptor in neonatal sheep. Endocrinology 142:2854–2864, 2001
